<SEC-DOCUMENT>0001193125-20-003036.txt : 20200107
<SEC-HEADER>0001193125-20-003036.hdr.sgml : 20200107
<ACCEPTANCE-DATETIME>20200107161603
ACCESSION NUMBER:		0001193125-20-003036
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200107
DATE AS OF CHANGE:		20200107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		20513489

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d860652d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amrn="http://www.amarincorp.com/20200107" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2020-01-07_to_2020-01-07">AMARIN CORP PLC\UK</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-01-07_to_2020-01-07">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-01-07_to_2020-01-07">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-01-07_to_2020-01-07">0000897448</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amrn-20200107.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-01-07_to_2020-01-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000897448</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-07</xbrli:startDate> <xbrli:endDate>2020-01-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">WASHINGTON, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:10pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-01-07_to_2020-01-07">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:10pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section 13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:10pt">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt:datemonthdayyearen">January 7, 2020</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:10pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amarin Corporation plc</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:10pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-01-07_to_2020-01-07">0-21392</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not applicable</span> </p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">of incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(I.R.S. Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:50%;"></td>
<td style="width:1%;"></td>
<td style="width:49%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-01-07_to_2020-01-07">77 Sir John Rogerson&#8217;s Quay</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-01-07_to_2020-01-07">Block C</ix:nonNumeric>,</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2020-01-07_to_2020-01-07">Grand Canal Docklands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-01-07_to_2020-01-07">Dublin</ix:nonNumeric>&#32;<ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-01-07_to_2020-01-07">2</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:countrynameen">Ireland</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Not applicable</p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:10pt">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-01-07_to_2020-01-07">+353 1</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-01-07_to_2020-01-07">6699 020</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:10pt">Not Applicable</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Former name or former address, if changed since last report</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:10pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:10pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-01-07_to_2020-01-07">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-01-07_to_2020-01-07">AMRN</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:exchnameen">NASDAQ Stock Market LLC</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:10pt">Emerging growth company &#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-01-07_to_2020-01-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:0"></p></div>

<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;2.02. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Results of Operations and Financial Condition.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">On January&#160;7, 2020, Amarin Corporation plc issued a press release announcing its preliminary 2019 financial results and further details on its 2020 outlook (the &#8220;Press Release&#8221;). A copy of the Press Release is furnished herewith as Exhibit 99.1. </p> <p style="font-family:Times New Roman;font-style:italic;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The information in this report furnished pursuant to Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d) Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:92%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit <br />No. </p> </td>
<td style="white-space:nowrap;vertical-align:bottom;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d860652dex991.htm">Press Release, dated January 7, 2020 </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document) </p> </td> </tr> </table> <p style="font-family:Times New Roman;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">* * * </p> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:46%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:2%;"></td>
<td style="width:1%;"></td>
<td style="width:45%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: January&#160;7, 2020 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Amarin Corporation plc </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ John F. Thero </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">John F. Thero </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">President and Chief Executive Officer </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d860652dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g860652g0107100846885.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above <FONT STYLE="white-space:nowrap">Upper-End</FONT> of Prior
Guidance of $410 to $425 Million </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U.S. Sales Force Expansion <FONT STYLE="white-space:nowrap">On-Track</FONT> for Doubling to 800
Sales Professionals in Early 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Full-Year 2020 Net Total Revenue Guidance Reiterated at $650 to $700 Million, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Predominately from U.S. Sales of VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 7, 2020 &#151; Amarin Corporation plc (NASDAQ:AMRN), today provided a business update, including an update of
preliminary 2019 results and additional 2020 financial guidance. Amarin plans to discuss these results and expectations with investors in connection with the 38<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual J.P. Morgan Healthcare
Conference in San Francisco, California, at which Amarin is scheduled to present on Wednesday, January&nbsp;15, 2020, at 10:30 a.m. Pacific Time (PT) / 1:30 p.m. Eastern Time (ET). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary (unaudited) 2019 Financial Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record
Revenue Levels: </B>2019 net total revenue, subject to audit, are expected to be at or potentially slightly above the <FONT STYLE="white-space:nowrap">upper-end</FONT> of the company&#146;s previously expressed guidance of $410 to $425&nbsp;million,
this upper end representing an increase of ~85% over 2018 results. Net total revenue consists predominantly of U.S. sales driven by increased prescriptions for VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl)
capsules. Wholesaler inventory levels of VASCEPA were within normal industry ranges at the end of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Assets: </B>Amarin ended 2019 with
approximately $645&nbsp;million in cash, approximately $117&nbsp;million in net accounts receivable and approximately $76&nbsp;million in inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Debt, Except Remaining Balance of Royalty-Bearing Instrument: </B>Amarin ended 2019 with no debt except the remaining balance on its royalty-bearing
instrument which is repaid at a rate of 10% of VASCEPA revenue until this royalty-like obligation is fulfilled; aggregate repayment of less than $55&nbsp;million remained as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Financial and Operational Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;13, 2019, Amarin announced the approval of VASCEPA as the first and only drug with an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> indication for reducing cardiovascular risk in patients with persistent high cardiovascular risk
despite statin therapy as studied in the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> cardiovascular outcomes study. With this new indication, Amarin aims to help millions of patients
through aggressively launching VASCEPA in the United States while exploring additional international opportunities. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin is increasing its United States sales force to 800 sales representatives, up from 400 in most of
2019. Health professional targets will be expanded from approximately 50,000 to a planned 75,000 physicians along with planned increased frequency in the number of calls to these targets. The hiring of the expanded sales team is well underway as
more than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the new sales representatives are hired and in the process of being trained. The remaining sales professionals are targeted to be hired in January or early February 2020. While trained
sales representatives are already in the field with the new label for VASCEPA, the company&#146;s national sales launch meeting is scheduled for next week, after which the sales team will be more fully trained and more prepared for field promotion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Amarin is training select physicians to present VASCEPA to their peers and sponsoring various medical education programs that cover VASCEPA
starting this month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Amarin anticipates revenue growth to be stimulated by such activities, it is common for patients who are candidates for
VASCEPA to visit their physicians only once, sometimes twice, annually. As a result, similar to the experience of other therapies for treating chronic conditions, we do not anticipate prescription rates for VASCEPA to spike upwardly immediately. In
addition, historically, the first calendar quarter of each year has started relatively slowly due to a number of recurring seasonal factors that have also affected similarly situated prescription therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Branded <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> (DTC) promotion of VASCEPA for cardiovascular risk
reduction is subject to separate FDA approval which Amarin anticipates receiving by <FONT STYLE="white-space:nowrap">mid-2020</FONT> (submission was not possible until after the new label for VASCEPA was approved). Based on results shown for other
products, such DTC promotion when launched is anticipated to further accelerate VASCEPA revenue growth. Until such branded DTC promotion is permitted, the company anticipates various programs to increase awareness and remind physicians and consumers
that previously approved therapies are insufficient to address persistent cardiovascular risk for many patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Revenue Guidance:</B> Amarin
anticipates total net revenue in 2020 will be in a range of $650 to $700&nbsp;million, mostly from sales of VASCEPA in the United States. The guidance remains unchanged from the total net revenue guidance issued by the company on December&nbsp;13,
2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond 2020, Amarin reiterates that it believes that VASCEPA total net revenue will grow to reach multiple billions of dollars. The history of
other therapies for chronic conditions suggests that growth builds over multiple years. At this time, the company is not providing guidance regarding annual revenue levels beyond 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory Purchases:</B> Because the rate of VASCEPA revenue growth is difficult to predict, in 2020 Amarin intends to spend approximately
$250&nbsp;million on inventory purchases, which is approximately twice the amount spent for inventory purchases in 2019. Such planned purchases do not change Amarin&#146;s revenue guidance. Rather, the company believes they prepare Amarin, together
with existing inventory, for a situation in which actual revenue turns out to be significantly higher than the revenue guidance described above. One of the important features of VASCEPA is the product&#146;s stability achieved through the expert
manufacturing of its fragile single-active ingredient. This stability achievement presents limited financial risk of over-purchasing VASCEPA inventory as the product has demonstrated stability supporting approved commercial expiry dating through
four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Spending and Net Cash Flow:</B> Currently, Amarin anticipates operating expenses in 2020 to increase
approximately $200 to $250&nbsp;million over 2019 levels. Included in these amounts are previously described increased costs associated with the company&#146;s planned expansion of its sales team and <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
promotional activities, including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising. In the event that net product revenue grows faster than expected, selling, general and administrative
(SG&amp;A) expenses may be higher than reflected in this operating expense guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin, after being cash flow positive in the second and third
quarters of 2019, had net cash outflow of approximately $28&nbsp;million in the fourth quarter of 2019 reflecting the expansion of the company&#146;s sales force and other costs associated with the new
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> label for VASCEPA and the U.S. launch of this new label. Amarin anticipates starting 2020 with net cash outflows as it completes its sales force expansion and as these sales representatives become
productive and other forms of expanded promotion take hold. On a steady-state basis, including the expanded sales force size, but excluding incremental purchases to build inventory and incremental spending for launch-level DTC, Amarin estimates that
it needs approximately $150&nbsp;million in quarterly net revenue to collect adequate cash to achieve cashflow breakeven. During the <FONT STYLE="white-space:nowrap">ramp-up</FONT> phase, including the estimated higher cash outflow levels for
inventory build and DTC launch of a new indication, Amarin estimates that approximately $200&nbsp;million in quarterly net revenue is required to generate required cash collections to achieve cashflow breakeven. Above these breakeven levels,
additional cash inflows should be net positive. Amarin reiterates that it believes that its current cash resources are adequate to reach positive net cash flow based on VASCEPA following its launch for its new
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> cardiovascular risk reduction indication and reiterated that such spending levels are likely to vary quarterly. Amarin will consider added promotion as well as further sales force expansion if the
pace of revenue growth exceeds expectations and if such added promotion can be reasonably predicted to pay for itself on a reasonably prompt basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>International: </B>Internationally, Amarin currently has three partners for commercialization of VASCEPA in select geographies and intends to consider
potential additional partners to commercialize VASCEPA in other parts of the world. Amarin&#146;s partner HLS received approval of VASCEPA from Health Canada on December&nbsp;31, 2019. In the Middle East, Amarin&#146;s partner Biologix, received
approval for VASCEPA in two countries, Lebanon and the United Arab Emirates, with additional approvals in the region requested. In the Greater China region, Amarin&#146;s partner, Eddingpharm, continues to run the biomarker focused clinical study of
VASCEPA. The pace of patient enrollment in this trial has been increasing, positioning that study for potential completion in 2020, with the intention of making VASCEPA the first approved prescription drug of its type in Mainland China and other
markets in that region. With respect to commercialization partners for VASCEPA in other geographies, Amarin intends to continue to be receptive to inquiries from qualified companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comment from Amarin&#146;s President and CEO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Early feedback from physicians and medical societies has been positive regarding the new indication for VASCEPA,&#148; commented John F. Thero, president
and chief executive officer. &#147;Publications from both the AHA and ACC listed icosapent ethyl in their top cardiovascular news lists for 2019, a particularly major accomplishment as icosapent ethyl was on these lists for 2018 as well. With
extraordinary employees, broad support from leading physicians, good payor coverage, a large patient need, and the only approved indication to address this need, Amarin commences 2020 with confidence and focus. Our aim is to make VASCEPA a new
standard of care for the benefit of millions of patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin will provide further details regarding its 2019 results and plans to provide
further outlook for 2020 in connection with the company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> when filed near the end of February 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc is a rapidly
growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin&#146;s lead product, VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(icosapent ethyl), is available by prescription in the United States, Lebanon and the United Arab Emirates, and is expected to be available in Canada through an anticipated February 2020 commercial launch. Amarin, together with its commercial
partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit <U>www.amarincorp.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cardiovascular Disease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cardiovascular disease is
an enormous and growing medical issue worldwide.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> In the United States alone, a heart
attack, stroke, death or other major cardiovascular event is experienced every 14 seconds.<SUP STYLE="font-size:85%; vertical-align:top">2,</SUP><SUP STYLE="font-size:85%; vertical-align:top">3</SUP><SUP STYLE="font-size:85%; vertical-align:top">
</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Controlling bad cholesterol, also known as <FONT STYLE="white-space:nowrap">LDL-C,</FONT> is one way to reduce a patient&#146;s risk of
experiencing a cardiovascular event. However, even with the achievement of target <FONT STYLE="white-space:nowrap">LDL-C</FONT> levels, millions of patients still have significant and persistent cardiovascular risk, especially those patients with
high triglycerides. Statin therapy has been shown to control <FONT STYLE="white-space:nowrap">LDL-C,</FONT> thereby reducing the risk of cardiovascular events by <FONT STYLE="white-space:nowrap">25-35%</FONT> &#150; but that still leaves <FONT
STYLE="white-space:nowrap">65-75%</FONT> of risk remaining.<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> People with high triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking
statins.<SUP STYLE="font-size:85%; vertical-align:top">5</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">6</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP
STYLE="font-size:85%; vertical-align:top">7</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About VASCEPA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) Capsules
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA (icosapent ethyl) capsules are the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-and-only</FONT></FONT> prescription
treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drug&#146;s initial FDA approved
indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million
times and is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Indications and Limitation of Use </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VASCEPA is indicated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary
revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 150 mg/dL) and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established cardiovascular disease or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diabetes mellitus and two or more additional risk factors for cardiovascular disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As an adjunct to diet to reduce TG levels in adult patients with severe
(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;500 mg/dL) hypertriglyceridemia. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effect of VASCEPA on the risk for
pancreatitis in patients with severe hypertriglyceridemia has not been determined. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Important Safety Information </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or
any of its components. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring
hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic
reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled
trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the cardiovascular outcomes trial (incidence
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>3% and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial
fibrillation (5% vs 4%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Common adverse reactions in the hypertriglyceridemia trials (incidence &gt;1% more frequent than placebo):
arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events may be reported by calling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-855-VASCEPA</FONT></FONT> or the FDA at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-FDA-1088.</FONT></FONT></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents for bleeding should be
monitored. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies
section of the prescribing information for VASCEPA, as set forth below: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Effect of VASCEPA on Time to First Occurrence of Cardiovascular
Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VASCEPA<BR>vs Placebo</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N&nbsp;=&nbsp;4089</B><br><B>n(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate<BR>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>N&nbsp;=&nbsp;4090</B><br><B>n(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incidence<BR>Rate<BR>(per 100<BR>patient<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Hazard&nbsp;Ratio<BR>(95% CI)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Primary composite endpoint</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke, coronary revascularization,
hospitalization for unstable angina <FONT STYLE="white-space:nowrap">(5-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">705<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(17.2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">901<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(22.0)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.75<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.68,&nbsp;0.83)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key secondary composite endpoint</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death, myocardial infarction, stroke
<FONT STYLE="white-space:nowrap">(3-point</FONT> MACE)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">459<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(11.2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">606<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(14.8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.74<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.65,&nbsp;0.83)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="11"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other secondary endpoints</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> myocardial infarction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">250<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(6.1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">355<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(8.7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.69<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.58,&nbsp;0.81)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emergent or urgent coronary revascularization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">216<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5.3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">321<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(7.8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.65<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.55,&nbsp;0.78)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiovascular death <SUP STYLE="font-size:85%; vertical-align:top">[1]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">174<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(4.3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">213<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(5.2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.80<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.66,&nbsp;0.98)</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hospitalization for unstable angina
<SUP STYLE="font-size:85%; vertical-align:top">[2]</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">108<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2.6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">157<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3.8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.68<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.53,&nbsp;0.87)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatal or <FONT STYLE="white-space:nowrap">non-fatal</FONT> stroke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">98<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(2.4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">134<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(3.3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">0.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.72<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(0.55,&nbsp;0.93)</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[1]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes adjudicated cardiovascular deaths and deaths of undetermined causality. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">[2]</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Determined to be caused by myocardial ischemia by <FONT STYLE="white-space:nowrap">invasive/non-invasive</FONT>
testing and requiring emergent hospitalization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FULL VASCEPA <U>PRESCRIBING INFORMATION</U> CAN BE FOUND AT <U>WWW.VASCEPA.COM</U>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements, including expectations regarding prescription growth and revenue growth from sales of VASCEPA; expectations that <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> results could lead to a new treatment paradigm in
the patient population studied; expectations regarding managed care coverage for VASCEPA; expectations regarding levels of operating spending and levels of inventory purchases and plans for commercial and international expansion. These
forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In addition, Amarin&#146;s ability to effectively commercialize VASCEPA will depend in part on its ability to continue to effectively finance
its business, efforts of third parties, its ability to create market demand for VASCEPA through education, marketing and sales activities, to achieve market acceptance of VASCEPA, to receive adequate levels of reimbursement from third-party payers,
to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA and to maintain patent protection for VASCEPA. Among the
factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approvals; the risk that sales may not meet expectations and related cost may increase beyond expectations; the risk that patents may not be determined to be infringed or upheld in
patent litigation and applications may not result in issued patents sufficient to protect the VASCEPA franchise. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in
Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or
otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Other Information About Amarin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and others should note that Amarin communicates with its investors and the public using the company website (<U>www.amarincorp.com</U>), the investor
relations website (<U>investor.amarincorp.com</U>), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin
posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor
relations website, on a regular basis. This list of channels may be updated from time to time on Amarin&#146;s investor relations website and may include social media channels. The contents of Amarin&#146;s website or these channels, or any other
website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amarin Contact Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Inquiries:
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elisabeth Schwartz </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT
STYLE="white-space:nowrap">719-1315</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor.relations@amarincorp.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee M. Stern </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solebury Trout </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (646) <FONT STYLE="white-space:nowrap">378-2992</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lstern@soleburytrout.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media Inquiries: </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gwen Fisher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amarin Corporation plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In U.S.: +1 (908) <FONT
STYLE="white-space:nowrap">325-0735</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>pr@amarincorp.com </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association. Heart Disease and Stroke Statistics &#150; 2019 Update: A Report from the American
Heart Association. Published January&nbsp;31, 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association / American Stroke Association. 2017. Cardiovascular disease: A costly burden for
America projections through 2035. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">American Heart Association: Heart Disease and Stroke Statistics &#151; 2019 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">At-a-Glance.</FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia
management. J Am Coll Cardiol. <FONT STYLE="white-space:nowrap">2018;72(3):330-343.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am
J Cardiol. <FONT STYLE="white-space:nowrap">2016;118:138-145.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events,
medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. Circ Res. <FONT STYLE="white-space:nowrap">2016;118:547-563.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amrn-20200107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.14 - Release 2019.4 -->
<!-- Creation date: 1/8/2020 12:48:49 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:amrn="http://www.amarincorp.com/20200107"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amarincorp.com/20200107"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20200107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amrn-20200107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>amrn-20200107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.14 - Release 2019.4 -->
<!-- Creation date: 1/8/2020 12:48:49 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>amrn-20200107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.14 - Release 2019.4 -->
<!-- Creation date: 1/8/2020 12:48:49 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amrn-20200107.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g860652g0107100846885.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g860652g0107100846885.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] 2\# 2(  A$! Q$!_\0
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MPZ$$9!J6N,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.X/]*5-+DO3W'-OFM(^E_"7A>T\):%%IMJQD(.Z65A@R.>IJ'Q[_ ,B)K/\
MU[-6KI&JVNMZ5;ZC92!X)T#*?3V/O65X]_Y$36?^O9JY%=SU-W;ET/E3^'\*
M^K/ ?_(BZ+_UZ)_*OE/^'\*^K/ ?_(BZ+_UZ)_*NK%?"C&CNSB_C?_QX:#_U
M^_X5Z<UO#=6'V>XC66&2/:Z.,A@1R#7F/QO_ ./#0?\ K]_PKU.'_41_[H_E
M7-+X(_,U7Q,^<?B-\/9O"=X;ZQ5I-'F;Y6ZF!C_"WMZ&L7P;XPOO!VL"[M\R
M6LF!<VQ/$B^H]&'8U]27EG;W]G+:7<*36\RE)(W&0P-?-OQ!\ W'@_4/.MP\
MNDSM^YE/)C/]QO?T/>NBE54UR2,IP<7S1/?HM:L=?\)SZCI\PEMY;9R#W4[3
MD$=B*Y7X*C'P^C/K<R_SKQGPIXOO?"\EU''NEL;N-HY[?/!)! 8>C#]17M/P
M7&/A[#[W$O\ Z%6=2GR1:+C/F:/0J***YS40D*N2< =37$^-/B1I'AK3I4M;
MJ&\U1UQ#!$P8*?[SD= /S-=E<V\5Y:RVTZ;X9D,;KG&5(P17(I\*/!*<+H:8
M_P"NTG_Q57#EO[Q,N;H<3\%=0T[[1K-Q?WD0UBYE#$S.%9TY)(SU^8\_A7LZ
M.KKN1@RGH0<BN0/PK\%'KH<7_?V3_P"*KH])T>PT+3TL--MQ;VJ$E8P20"3D
M]33J2C)W0H)I69>HZ44UT62-D<95A@CVK,LXKXG3Z-/X&U&"^O+=9-FZ!=X+
M&0<K@=>M?-/:OIW_ (5=X*SG^P8<^OF/_P#%4O\ PJ_P7_T 8?\ OX__ ,57
M32K1@K:F,X2D[GG/PD\>VFCQR:%K%R(+=WWVTTAPJ,>JD]@>M=A\6=>TX> K
MFVBOH))KLJD21R!BPR"3QVQ6M_PJ[P5_T 8?^_C_ /Q5(/A;X*'30(!_VT?_
M .*J7.FY\VHU&2C89\-=9T^]\#Z;#!=1&6WC\J6,L RL#W%/^)7AO_A)/"%Q
M'$F;NV_?P>N1U'XCBGQ?#+P;#,DT>APK(C!E82/P1_P*NL(!&",@U#DE+FB6
MD[69X!\&?#?]I>(9-8G0^18#"9'64]/RKWUY$C&7=5'JQQ533-(L-'@D@T^V
M2WBDD:5E7NS=35?7?#6D^);>.#5K3[1'&VY%WLN#^!%%2?/*[%&/*K'SA\1K
MB&Z\?ZM+!*DL9D #H<@X [UUWP1OK2SU'5_M5U#!NA4CS7"Y //6O1/^%4>"
MA_S!5_[_ ,G_ ,52'X4>"3UT1#_VVD_^*K9UH.'*0J<E+F.*USQ9H_C+XB:7
MI4MT@T.TE+-([82>4=.?2O8HX[9T!C2)EQP5 (KD_P#A5'@HC_D"+_W_ )/_
M (JM[0O#>D^&K>2WTFU^SQ2-N9=[-D_\")K*<HM+E+BI)ZF@;>'',,?_ 'R*
M\O\ C+HVF7'AU-322WBO;5PJ@, 9%/5<=Z]4(R,'O7)R_#/P=/,\TNAPO([%
MF8R/R3U_BJ:<E&5V.2NK'S-97L^G7T%[;.4G@<.C#U%?4WA;Q7I_B70X+Z&X
MB$I4":(N T;]P15#_A5W@O\ Z ,/_?R3_P"*H_X5=X+S_P @&'_OY)_\56M6
MI"H1"$HGA'Q$N(;GQ[JTL$B21F7 9#D' ]:[7X%W5O#?:M%+/&DCHA1&8 L!
MG.*]!_X5=X*_Z ,/_?Q__BJ/^%7>"O\ H P_]_)/_BJJ5:#ARB5.2ES'4W$$
M%]9RV\R++!,A1U/(8&OEKQIX8F\*>))[!@3 Q\RW<_Q(>GXCI7U)8V-MIME#
M9V<0BMX5V1H"3M'XUG:]X5T7Q,L*ZO8I<^228R692N>O((K*E4Y'Y%SAS(\3
M^$_CA- U$Z1J,P33KILH[GB&3^@/\Z]:\>W]G_P@6K'[5#A[<A,2#YB<8QZU
M7_X53X*_Z J_]_Y/_BJ4?"KP4!_R XSCIF:3_P"*JISA*7,3&,DK'S'_  _A
M7U%X!U2PG\#Z3Y=U#F.V5'7S!E2!@@CM47_"K/!7_0#C_P"_LG_Q5)_PJKP5
MG_D!1?\ ?V3_ .*JJM6%16%"$HLXCXT^(-.N9-(L+>YCGFMYO/F\I@P1>, X
M[\'BO6M+U2QU.P@GLKN&>-T!4HX/:N<_X57X*'30HA_VUD_^*J]I?@'POHNH
M1WVG:3'!=19V2*[DC(P>IQ6<I0<4ET+2E>YTE5=1TZTU;3YK&^@6:VF7:Z,.
M"/\ 'WJU1619\O>._ UWX-U/'S3:;,Q^SW&/_'&_VA^M>P_!H$?#VWSWN)3_
M ./&NRU?2;+7-+GT_4(%FMIEPRGJ/0@]B/6JGAGPY:>%=&CTJRDFDA1V<-,0
86RQR>@%;SJ\\+/<SC#EE=&S1116!H?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["SMO[-'^8^.;8%/#K[MHO@!02P,$%     @  8(G4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MQ\$R3)B(<>?2'GE!W[O;TW #$B$NO5XJ^6B24N:<B7_ZSJ%_7.\W4$L#!!0
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  8(G4)E<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  !@B=0MZEJK+4"  !?#   &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  8(G4!J2@:&I @
MZ08  !0              ( !XPL  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @  8(G4+JA.8K7 0  ,@8   T              ( !O@X  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  !@B=0%FTC?T,!   \ @  #P
M        @ ' $   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  8(G4/_
M)@B]    A0(  !H              ( !,!(  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @  8(G4 N/V ,A 0  5P0  !,
M     ( !)1,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @
&=Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d860652d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amrn-20200107.xsd" xlink:type="simple"/>
    <context id="duration_2020-01-07_to_2020-01-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000897448</identifier>
        </entity>
        <period>
            <startDate>2020-01-07</startDate>
            <endDate>2020-01-07</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2020-01-07_to_2020-01-07"
      id="Hidden_dei_EntityRegistrantName">AMARIN CORP PLC\UK</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2020-01-07_to_2020-01-07"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2020-01-07_to_2020-01-07">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-01-07_to_2020-01-07"
      id="Hidden_dei_EntityCentralIndexKey">0000897448</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-01-07_to_2020-01-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-01-07_to_2020-01-07">2020-01-07</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-01-07_to_2020-01-07">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-01-07_to_2020-01-07">0-21392</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-01-07_to_2020-01-07">77 Sir John Rogerson&#x2019;s Quay</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-01-07_to_2020-01-07">Block C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2020-01-07_to_2020-01-07">Grand Canal Docklands</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-01-07_to_2020-01-07">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-01-07_to_2020-01-07">2</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="duration_2020-01-07_to_2020-01-07">IE</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="duration_2020-01-07_to_2020-01-07">+353 1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-01-07_to_2020-01-07">6699 020</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-01-07_to_2020-01-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-01-07_to_2020-01-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-01-07_to_2020-01-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-01-07_to_2020-01-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-01-07_to_2020-01-07">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-01-07_to_2020-01-07">AMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-01-07_to_2020-01-07">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-01-07_to_2020-01-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>9
<FILENAME>0001193125-20-003036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-003036-xbrl.zip
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M[2"3U4EN;KH37U_5&P=__@102P,$%     @  8(G4$_,':F=!@  "TH  !4
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M?X;9B0<G!UQ4E^.SLBW._^ 8Y2+<"\VM+C!O3Z_OF _S+K N^1M02P,$%
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M_/=-9DN\,>2L3YKQ&[:NS1NVY$-UJRU+2!=Y\U_/79C_F*[V?U!+ P04
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M#Z,--!)S+#693%*$K$X!W=_DV='*&1!?>X)$V#;MZ2_P!IB2 U;J\%,_\?I
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M@'2 -TE)U #ZD)3 :".C]#.E/@R(>QT@E7:I@SZ&57,$O=.1CBU9,^J3-1*
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MXJ=(M=[,VWI3VU#K'!F; :)FJW''*!ETWS#9( TO1Q8OV=S+&809+F01-"=
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M.;Y/A^/.QE:]L_D$8^"'B^EL/QS3V7][>''\&WSYX>;C^<'_!U!+ 0(4 Q0
M   (  &")U +)I&W9@,  "T,   1              "  0    !A;7)N+3(P
M,C P,3 W+GAS9%!+ 0(4 Q0    (  &")U!/S!VIG08   M*   5
M      "  94#  !A;7)N+3(P,C P,3 W7VQA8BYX;6Q02P$"% ,4    "  !
M@B=07\J"G]D$  "%+@  %0              @ %E"@  86UR;BTR,#(P,#$P
M-U]P<F4N>&UL4$L! A0#%     @  8(G4.#90<2E#P  .G(   X
M     ( !<0\  &0X-C V-3)D.&LN:'1M4$L! A0#%     @  8(G4+*BC=Y-
M*0  *=<  !$              ( !0A\  &0X-C V-3)D97@Y.3$N:'1M4$L%
3!@     %  4 0 $  +Y(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6627464864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMARIN CORP PLC\UK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000897448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  07,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-21392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">77 Sir John Rogerson&#8217;s Quay<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Block C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Grand Canal Docklands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+353 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6699 020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) Ordinary Share of Amarin Corporation plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>11
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d860652d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d860652d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amrn-20200107_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amrn-20200107_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amrn-20200107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "amrn",
   "nsuri": "http://www.amarincorp.com/20200107",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d860652d8k.htm",
      "contextRef": "duration_2020-01-07_to_2020-01-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d860652d8k.htm",
      "contextRef": "duration_2020-01-07_to_2020-01-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d860652d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amarincorp.com//20200107/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d860652d8k.htm">d860652d8k.htm</File>
    <File>amrn-20200107.xsd</File>
    <File>amrn-20200107_lab.xml</File>
    <File>amrn-20200107_pre.xml</File>
    <File>d860652dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
